Dstock,
Great post. Bosch’s presentation showing they found 399 tumor-associated peptides in one DCVax lysate and you showing a list of other cancers that share these peptides, just further validates to me that the DCVax technology platform is tissue agnostic and will be effective against other cancers.
Given other cancer drugs typically just target a single or a couple of antigens, the scale at which DCVax is jumping forward is really amazing. The scale is that DCVax hits all the tumor antigens, meaning it will attack the tumor from 399 different points. I interpret that, wrt cancer patient, to be no tumor escape and a better chance of no cancer metastases.
My other recollection from Bosch is that DCVax not only presents MHC class 1 but MHC class 2 antigens too. That is an important detail because CD4 T cells only pick up MHC class 2 antigens. Add that CD4 T cells are memory T cells, then that is effectively how a patient will get systemic immune memory for that cancer.
This is the renaissance I see coming. Immune memory is the basis for any real future cure of cancer. And all of this is unique to DCVax.
Bullish
News 
Market Data 
Discover 
AI
